ArticleGastroenterology & hepatology2026
Update on Pregnancy in Inflammatory Bowel Disease.
Article in Gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ongoing clinical and population health research continues to inform evidence-based management of patients with inflammatory bowel disease during pregnancy. Advances in noninvasive tools for disease monitoring highlight the expanding role of intestinal ultra-sound for point-of-care assessments throughout pregnancy. Updates in medical management include recent data demonstrating the association between thiopurines and intrahepatic cholestasis of pregnancy, the role of low-dose aspirin in preventing hypertensive disorders of pregnancy, and guidance related to Janus kinase inhibitor safety. Evolving pharmacologic data inform the safety and increasing use of biosimilars during pregnancy, the emergence of newer targeted therapies such as selective interleukin-23p19 inhibitors, and emerging evidence to support the safety of rotavirus vaccination in infants exposed to biologics in utero. This article summarizes several key updates on diagnostics, treatment, and preventative care strategies aimed at improving maternal and fetal health.
Indexed as
Identifiers
42389327PMC13322327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.